India is expected to maintain dominance in the market.
A rise in direct healthcare costs, development of hi-tech diagnostic products, and demand from middle and low-income countries has driven the growth for hospital-acquired infection diagnostics in Asia Pacific, according to a report from Allied Market Research.
The market generated $418.93m in 2019, and is projected to get $780.88m by 2027 at a CAGR of 7.5% from 2020. India contributed to the highest market share in 2019, accounting for nearly one-tenth of the total share.
The country is also expected to maintain its dominant share by 2027, and is projected to witness the highest CAGR of 8.5% during the period.
A lack of awareness and consequences of antibiotic-resistant infections might hold back the market growth. However, awareness programs by various organizations and supportive government initiatives are expected to create new opportunities in the next few years.
Further, the development of easy-to-use and quick result-delivering devices has been carried out by diagnostic test manufacturers to support testing outside of laboratory settings for COVID-19, as there has been shortage of laboratory-based molecular testing capacity.
The report noted that in the regions severely affected by the pandemic, surgical procedures have been reduced to life or limb salvage cases only as per the new government directives or hospital guidelines.
“This measure would make hospital beds and healthcare providers available for coronavirus-infected patients. In addition, there will be saving of personal protective equipment and probability of viral transmission would be reduced among patients and staff,” the report added.
Do you know more about this story? Contact us anonymously through this link.